BioMarin Pharmaceutical Inc. (BMRN) Announces BMN-673 Data in Breast and Ovarian Cancers to be Released at American Society of Clinical Oncology
5/17/2013 9:15:56 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
SAN RAFAEL, Calif., May 16, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced that data from its ongoing Phase 1/2 trial for BMN-673 for genetically-defined cancers will be released at the American Society of Clinical Oncology (ASCO) meeting in Chicago on June 3, 2013. At ASCO, the company will present data from 18 gBRCA breast cancer patients, including six patients from the dose escalation cohort at doses ranging from 25 µg to 1100 µg and twelve patients from the dose expansion cohort at a dose of 1.0 mg. Data will also be presented from 28 gBRCA ovarian cancer patients, including 17 patients from the dose escalation cohort and 11 patients from the dose expansion cohort.
Help employers find you! Check out all the jobs and post your resume.